EXAMORELIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C47H58N12O6
Molecular Weight	887.0402
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](NC(=O)[C@@H](CC1=C(C)NC2=CC=CC=C12)NC(=O)[C@@H](N)CC3=CN=CN3)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(=O)N[C@H](CC6=CC=CC=C6)C(=O)N[C@@H](CCCCN)C(N)=O

InChI

InChIKey=RVWNMGKSNGWLOL-GIIHNPQRSA-N

InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C47H58N12O6
Molecular Weight	887.0402
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8126144 | https://www.ncbi.nlm.nih.gov/pubmed/25278975 | https://adisinsight.springer.com/drugs/800003697

Examorelin (Hexarelin) is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates the release of growth hormone lease through binding to the growth hormone secretagogue receptor (GHSR). Hexarelin might have direct cardiovascular actions beyond growth hormone release and neuroendocrine effects. Europeptides and Mediolanum Farmaceutici were developing examorelin for the treatment of somatotropin deficiency.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ghrelin receptor 15 Target ID: CHEMBL4616 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12646029\|https://www.ncbi.nlm.nih.gov/pubmed/12486113\|https://www.ncbi.nlm.nih.gov/pubmed/8126144\|https://www.ncbi.nlm.nih.gov/pubmed/28321024	Agonist 2752		18.0 nM [IC50]
Platelet glycoprotein 4 3 Target ID: CHEMBL2163174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22712585\|https://www.ncbi.nlm.nih.gov/pubmed/23302781	Agonist 2752		2.08 µM [IC50]

PubMed

Title	Date	PubMed
Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat.	2010-04	19931584
The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.	1995-09	7673411
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.	1994-03	8126144

Patents

Sample Use Guides

In Vivo Use Guide

i.v. (1 and 2 ug/kg), sc (1.5 and 3 ug/kg), intranasal (20 ug/kg), and oral (po; 20 and 40 mg)

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:24:21 GMT 2025` Edited by `admin` on `Wed Apr 02 09:24:21 GMT 2025`
Record UNII	09QF37C617
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EXAMORELIN

Official Name

English

EP-23905

Preferred Name

English

EXAMORELIN [MART.]

Common Name

English

examorelin [INN]

Common Name

English

L-HISTIDYL-2-METHYL-D-TRYPTOPHYL-L-ALANYL-L-TRYPTOPHYL-D-PHENYLALANYL-L-LYSINAMIDE

Systematic Name

English

MF-6003

Code

English

HEXARELIN

Common Name

English

L-LYSINAMIDE, L-HISTIDYL-2-METHYL-D-TRYPTOPHYL-L-ALANYL-L-TRYPTOPHYL-D-PHENYLALANYL-

Systematic Name

English

Classification Tree Code System Code

WIKIPEDIA

Designer-drugs-Examorelin